Last reviewed · How we verify
Bacillus Calmette-Guerin: Strain TICE
BCG TICE is a live attenuated mycobacterial vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.
BCG TICE is a live attenuated mycobacterial vaccine that stimulates innate and adaptive immune responses to enhance anti-tumor immunity. Used for Non-muscle invasive bladder cancer (NMIBC), Potentially other solid tumors (investigational).
At a glance
| Generic name | Bacillus Calmette-Guerin: Strain TICE |
|---|---|
| Also known as | OncoTICE |
| Sponsor | Verity Pharmaceuticals Inc. |
| Drug class | Live attenuated vaccine / Immunotherapy |
| Target | Pattern recognition receptors (TLR2, TLR4, NOD2); non-specific immune activation |
| Modality | Small molecule |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
BCG (Bacillus Calmette-Guerin) TICE strain is an intracellular pathogen that activates dendritic cells, macrophages, and T cells through pattern recognition receptors, promoting a Th1-type immune response. When administered intravesically or systemically, it enhances both local and systemic anti-tumor immunity, particularly useful in bladder cancer and potentially other malignancies. The mechanism leverages the immunogenicity of the live attenuated mycobacterium to prime the immune system against tumor-associated antigens.
Approved indications
- Non-muscle invasive bladder cancer (NMIBC)
- Potentially other solid tumors (investigational)
Common side effects
- Dysuria / urinary frequency
- Hematuria
- Fever
- Fatigue
- BCG infection / systemic toxicity
- Cystitis
Key clinical trials
- S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (PHASE3)
- Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (PHASE3)
- Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans (PHASE1)
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] (PHASE2)
- A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. (PHASE1, PHASE2)
- Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (PHASE2)
- Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment (PHASE1, PHASE2)
- BCG Vaccine for Health Care Workers as Defense Against COVID 19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: